Palliation and survival after repeated 188Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis.
Federica
F
Orsini
Federica
F
Guidoccio
Sara
S
Mazzarri
Giuliano
G
Mariani
D001859:Bone Neoplasms / Q000556:secondary* / Q000628:therapy*; D019008:Drug Resistance, Neoplasm / Q000528:radiation effects*; D012968:Etidronic Acid / Q000627:therapeutic use*; D006728:Hormones / Q000494:pharmacology*; D006801:Humans; D008297:Male; D009942:Organometallic Compounds / Q000627:therapeutic use*; D010166:Palliative Care / Q000379:methods*; D011471:Prostatic Neoplasms / Q000473:pathology*
D006728:Hormones; D009942:Organometallic Compounds; D012968:Etidronic Acid